-transparent.png){kind=logo}
The efficacy of low-dose bromocriptine mesylate administration (20 mg daily or less) was evaluated in a double-blind study. Nine of 16 individuals receiving bromocriptine completed the 40-week study. Modest, but significant, improvement was derived from bromocriptine therapy. Improvement was most evident in tremor. Maximum improvement was achieved with doses between 7.5 and 15.0 mg daily, with some decline in efficacy as doses approached 20 mg. Adverse effects were common, but were generally mild in severity. Our results suggest that bromocriptine in low doses may be an effective adjunct to carbidopa and levodopa (Sinemet) in the treatment of Parkinson's disease.
Related Publications
R F Pfeiffer, and
K Wilken, and
C Glaeske, and
A S Lorenzo
January 1984,
Clinical neuropharmacology,
R F Pfeiffer, and
K Wilken, and
C Glaeske, and
A S Lorenzo
January 1986,
Clinical neuropharmacology,
R F Pfeiffer, and
K Wilken, and
C Glaeske, and
A S Lorenzo
April 1985,
Journal of neurology, neurosurgery, and psychiatry,
R F Pfeiffer, and
K Wilken, and
C Glaeske, and
A S Lorenzo
January 1985,
Clinical neuropharmacology,
R F Pfeiffer, and
K Wilken, and
C Glaeske, and
A S Lorenzo
February 1986,
Neurology,
R F Pfeiffer, and
K Wilken, and
C Glaeske, and
A S Lorenzo
February 1984,
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,
R F Pfeiffer, and
K Wilken, and
C Glaeske, and
A S Lorenzo
June 1982,
Neurology,
R F Pfeiffer, and
K Wilken, and
C Glaeske, and
A S Lorenzo
April 1987,
Clinical neuropharmacology,
R F Pfeiffer, and
K Wilken, and
C Glaeske, and
A S Lorenzo
January 1986,
Bulletin of clinical neurosciences,
R F Pfeiffer, and
K Wilken, and
C Glaeske, and
A S Lorenzo
April 1985,
Neurology,
